| Literature DB >> 30316805 |
Zhijie Wu1, Valentina Giudice1, Jichun Chen1, Wanling Sun1, Zenghua Lin1, Keyvan Keyvanfar1, Nidhi Talasani1, Sachiko Kajigaya1, Xingmin Feng2, Neal S Young1.
Abstract
Interleukin-18 (IL-18), also known as interferon-gamma (IFN-γ)-inducing factor, is involved in Th1 responses and regulation of immunity. Accumulating evidence implicates IL-18 in autoimmune diseases, but little is known of its role in acquired aplastic anemia (AA), the immune-mediated destruction of bone marrow (BM) hematopoietic stem and progenitor cells (HSPCs). IL-18 protein levels were significantly elevated in sera of severe AA (SAA) patients, including both responders and nonresponders assayed before treatment, and decreased after treatment. IL-18 receptor (IL-18R) was expressed on HSPCs. Co-culture of human BM CD34+ cells from healthy donors with IL-18 upregulated genes in the helper T-cell and Notch signaling pathways and downregulated genes in the cell cycle regulation, telomerase, and IL-6 signaling pathways. Plasma IL-18 levels were also elevated in murine models of immune-mediated BM failure. However, deletion of IL-18 in donor lymph node cells or deletions of either IL-18 or IL-18R in recipients did not attenuate elevations of circulating IFN-γ, tumor necrosis factor-alpha, or IL-6, nor did they alleviate BM failure. In summary, our findings suggest that, although increased circulating IL-18 is a feature of SAA, it may reflect an aberrant immune response but be dispensable to the pathogenesis of AA. Published by Elsevier Inc.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30316805 PMCID: PMC6309608 DOI: 10.1016/j.exphem.2018.10.003
Source DB: PubMed Journal: Exp Hematol ISSN: 0301-472X Impact factor: 3.084